Electronic alerts to improve management of heparin-induced thrombocytopenia.

heparin medical order entry systems quality improvement thrombocytopenia

Journal

Research and practice in thrombosis and haemostasis
ISSN: 2475-0379
Titre abrégé: Res Pract Thromb Haemost
Pays: United States
ID NLM: 101703775

Informations de publication

Date de publication:
May 2024
Historique:
received: 21 02 2024
revised: 04 04 2024
accepted: 10 04 2024
medline: 2 7 2024
pubmed: 2 7 2024
entrez: 2 7 2024
Statut: epublish

Résumé

Heparin-induced thrombocytopenia (HIT) is a difficult clinicopathologic diagnosis to make and to treat. Delays in identification and appropriate treatment can lead to increased morbidity and mortality. To use electronic health alert interventions to improve provider diagnosis and management of heparin-induced thrombocytopenia through guideline-based, accurate care delivery. This quality improvement initiative developed 3 electronic health record-based interventions at our 750-bed academic medical center to improve the initial management of suspected HIT between 2018 and 2021: 1. an interruptive alert to recommend discontinuation of active heparin products when signing a heparin-platelet factor 4 test (PF4) order, 2. integrated 4T score calculation in the heparin-PF4 test order, and 3. interruptive alert suggesting not to order heparin-PF4 tests when the 4T score is <4. Changes in practice were assessed over defined time periods pre and post each intervention. Intervention 1 resulted in heparin discontinuation in more patients, with 65% (191 heparin orders/293 heparin-PF4 enzyme-linked immunosorbent assay tests) of cases continuing heparin prealert and only 54% (127 heparin orders/235 heparin-PF4 enzyme-linked immunosorbent assay tests) postinterruptive alert (95% CI 2.3-19.9;  Implementation of unique electronic health record interventions, including both diagnostic and management interventions, led to improved guideline-based, accurate care delivery with 4T score calculation and cessation of heparin for patients with suspected HIT.

Sections du résumé

Background UNASSIGNED
Heparin-induced thrombocytopenia (HIT) is a difficult clinicopathologic diagnosis to make and to treat. Delays in identification and appropriate treatment can lead to increased morbidity and mortality.
Objectives UNASSIGNED
To use electronic health alert interventions to improve provider diagnosis and management of heparin-induced thrombocytopenia through guideline-based, accurate care delivery.
Methods UNASSIGNED
This quality improvement initiative developed 3 electronic health record-based interventions at our 750-bed academic medical center to improve the initial management of suspected HIT between 2018 and 2021: 1. an interruptive alert to recommend discontinuation of active heparin products when signing a heparin-platelet factor 4 test (PF4) order, 2. integrated 4T score calculation in the heparin-PF4 test order, and 3. interruptive alert suggesting not to order heparin-PF4 tests when the 4T score is <4. Changes in practice were assessed over defined time periods pre and post each intervention.
Results UNASSIGNED
Intervention 1 resulted in heparin discontinuation in more patients, with 65% (191 heparin orders/293 heparin-PF4 enzyme-linked immunosorbent assay tests) of cases continuing heparin prealert and only 54% (127 heparin orders/235 heparin-PF4 enzyme-linked immunosorbent assay tests) postinterruptive alert (95% CI 2.3-19.9; 
Conclusion UNASSIGNED
Implementation of unique electronic health record interventions, including both diagnostic and management interventions, led to improved guideline-based, accurate care delivery with 4T score calculation and cessation of heparin for patients with suspected HIT.

Identifiants

pubmed: 38953054
doi: 10.1016/j.rpth.2024.102423
pii: S2475-0379(24)00112-2
pmc: PMC11215413
doi:

Types de publication

Journal Article

Langues

eng

Pagination

102423

Informations de copyright

© 2024 The Author(s).

Auteurs

Rebecca L Zon (RL)

Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
Division of Hematology, Brigham and Women's Hospital, Boston, Massachusetts, USA.
Harvard Medical School, Boston, Massachusetts, USA.

Katelyn W Sylvester (KW)

Department of Pharmacy, Brigham and Women's Hospital, Boston, Massachusetts, USA.

David Rubins (D)

Harvard Medical School, Boston, Massachusetts, USA.
Department of Medicine, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA.

Jessica Grandoni (J)

Department of Pharmacy, Brigham and Women's Hospital, Boston, Massachusetts, USA.

Julie Kelly (J)

Department of Pharmacy, Brigham and Women's Hospital, Boston, Massachusetts, USA.

Shreya Timilsina (S)

Department of Pharmacy, Brigham and Women's Hospital, Boston, Massachusetts, USA.

Mark Akladious (M)

Department of Pharmacy, Brigham and Women's Hospital, Boston, Massachusetts, USA.

Rajesh Patel (R)

Harvard Medical School, Boston, Massachusetts, USA.
Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts, USA.

Jean M Connors (JM)

Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
Division of Hematology, Brigham and Women's Hospital, Boston, Massachusetts, USA.
Harvard Medical School, Boston, Massachusetts, USA.

Classifications MeSH